Nucleai

Our CEO, Avi Veidman, was interviewed by Brian K. Buntz for Drug Discovery & Development! Avi shares how Nucleai's AI-driven spatial biomarkers aim to accelerate drug development: “We’re helping find the right drug for patients while making clinical trials shorter and more likely to succeed for pharma companies, potentially saving years and billions of dollars in drug development.” Learn how Nucleai is leading the way as the first company with an algorithm in active clinical trials. Read more: https://bit.ly/4f7Vl9S #SpatialBiology #AI #Oncology #SpatialBiomarkers #Biomarkers #ClinicalTrials #DigitalPathology #PrecisionMedicine #CDx

In honor of AI Appreciation Day, we had the privilege to interview Suzana Couto who serves as Senior Vice President of Pathology and Toxicology at Neomorph. Discover her insights and contributions in our latest blog post, where she shares her journey and the transformative power of AI in pathology. As Suzana shared, 'With whole-slide scanning and later AI-powered analysis — I just fell in love with the possibility of getting more quantitative data and spatial relationship data out of the images. AI has the potential to reshape clinical trials by empowering drug development teams to accelerate patient enrollment, optimize dosing, and ultimately get the right molecules to the right patients, faster.' Read the full interview here: https://bit.ly/3zIixeZ #AIAppreciationDay #AI #DigitalPathology #spatialbiomarkers #PrecisionMedecine

Happy AI Appreciation Day! 🌟 Today, we celebrate the transformative power of artificial intelligence and its incredible potential to reshape our world. From healthcare and finance to transportation and education, AI is revolutionizing how we approach complex challenges. 🚀 At Nucleai, we are proud to be at the forefront of AI-driven spatial biomarkers, advancing precision medicine and significantly improving patient care. 📷: The image accompanying this post was generated by ChatGPT and enhanced by Midjourney and Generative Fill by Photoshop. #AI #ArtificialIntelligence #AIAppreciationDay #SpatialBiomarkers #DigitalPathology #PrecisionMedicine

There was a recent announcement of a collaboration between Proscia and Nucleai. Here's a clip from Episode 135 where Dr Ken Bloom from Nucleai spoke about #spatialbiology and it's implications for #pathology. Full episode here: Apple: https://lnkd.in/gZq5uut Spotify: https://lnkd.in/gHqNMcb YouTube: https://lnkd.in/gTpuQhF6 Doc Social: https://lnkd.in/gSJdfJhP

We are honored to be named a 𝐅𝐢𝐫𝐞 𝐀𝐰𝐚𝐫𝐝 winner by the Chicago Business Journal, recognized as one of Chicago's top tech companies! 🔥🌠 Being featured in the 🔥𝐁𝐮𝐫𝐧𝐢𝐧𝐠 𝐇𝐨𝐭🔥 section showcases our rapid growth, new funding, and significant milestones. This honor underscores our commitment to innovative and disruptive technology in healthcare. Here's to breaking new ground and advancing precision medicine! 🚀🚀 https://lnkd.in/g5qMU-tR #precisionmedicine #AI #biomarkers #SpatialBiomarkers #PrecisionMedicine #Innovation #digitalpathology #FireAward

Proud to be featured in Sifted as part of Debiopharm Innovation Fund's strategic investments. With 97% of clinical trials for cancer therapies failing, our AI predictive biomarker solutions aim to turn the tide. We are committed to enhancing next-gen therapeutics and patient care. Grateful for the trust and confidence Debiopharm Innovation Fund has placed in us. Together, we’re set to transform the landscape of precision medicine. https://bit.ly/3XHj7mQ #AI #precisionmedicine #spatialbiomarkers #biomarkers #diagnostics #clinicaltrials #digitalpathology

Thrilled to integrate our predictive AI biomarkers with Proscia's digital pathology ecosystem! Together, we are set to revolutionize clinical trials, diagnostics, and patient care!

Proscia has partnered with Nucleai, a spatial AI biomarker company that maps protein expression and cellular interactions within tissue samples to predict therapeutic outcomes. The companies will integrate Nucleai’s predictive biomarker solutions into Proscia’s Concentriq® software platform making them available as part of Proscia’s precision medicine AI portfolio to optimize clinical trials and improve treatment decisions. As part of the collaboration Nucleai also joins Proscia Ready! “Together, Proscia and Nucleai will enable more pathologists and clinicians to convert the complex data from patient biopsies into precise, actionable insights that can drive better clinical trial and diagnostic decisions,” said Avi Veidman, Nucleai’s CEO. What's more... “Our partnership holds tremendous promise for advancing next-generation treatment modalities like ADCs, multispecifics, immunotherapy, and combination therapies. With the recent deployment of our technology to aid patient enrollment for an active trial and the growing need for AI-powered biomarkers across trials and diagnostics, this partnership represents a significant step forward in deploying our solutions, at scale. Together with Proscia, we can fundamentally improve the efficiency and effectiveness of introducing groundbreaking treatments and advancing patient care.” Read the article in full... https://lnkd.in/gxStmvC8 #digitalpathology #pathologynews

🚀 Our partnership with Proscia marks a major step forward in deploying AI biomarkers solutions at scale across clinical trials and diagnostics. Together, we're shaping the future of precision medicine. Read the full press release to learn more. https://bit.ly/3xAQvkQ #DigitalPathology #SpatialBiomarkers #Biomarkers #Dx #PrecisionMedicine #ClinicalTrials

🌟 Exciting News! 🌟 We're thrilled to announce that we have partnered with Proscia to integrate Nucleai's AI predictive biomarker solutions with Proscia's digital pathology ecosystem. This partnership will empower our biopharma partners in their clinical development programs by transforming complex biopsy data into precise, actionable insights. “Our partnership with Proscia holds tremendous promise for advancing next-generation treatments like ADCs, multispecifics, immunotherapy, and combination therapies. Together, we aim to improve the efficiency and effectiveness of groundbreaking treatments, enhancing patient care,” said Avi Veidman, Nucleai’s CEO. With the recent deployment of our technology to aid patient enrollment for an active trial and the growing need for AI-powered biomarkers across trials and diagnostics, this partnership represents a significant step forward in deploying our solutions, at scale. Stay tuned as we continue to drive innovation in digital pathology and precision medicine! 🚀 Read the full press release to learn more. https://lnkd.in/gfQbssGH #DigitalPathology #SpatialBiomarkers #Biomarkers #Dx #PrecisionMedicine #ClinicalTrials